Tuberculosis vaccine being tested in Phase II trial

Scientists have been working on an improved vaccine against the tuberculosis bacterium Mycobacterium tuberculosis for almost 90 years. The Bacillus Calmette-Guérin vaccine (BCG) was developed in the early 20th century and contains attenuated Mycobacterium bovis bacteria, the bovine tuberculosis pathogen that is transmissible to humans. BCG vaccination protects children in most cases against the disease, but not adults. Therefore, the vaccine has not contributed to reducing the global incidence of tuberculosis.

The VPM1002 vaccine, which was developed at the Max Planck Institute for Infection Biology, is based on the BCG vaccine and contains genetically modified Mycobacterium bovis bacteria. A built-in gene makes it easier for the immune cells to recognise the bacteria; the organism can thus protect itself against actual infection with dangerous tuberculosis pathogens. “VPM1002 is intended to replace the current BCG vaccine and will be administered to young children to protect them against tuberculosis. However, adults may also be able to benefit from it later,” says Stefan Kaufmann from the Berlin-based Max Planck Institute.

The vaccine candidate has been undergoing Phase II trials since November 2011. These should establish whether it is safe and tolerable for infants in regions with a high incidence of tuberculosis. A total of 48 infants are being immunised. No side-effects have emerged to date.

VPM1002 was licensed to Vakzine Projekt Management GmbH in Hanover, which carried out its entire pre-clinical development. The vaccine was initially tested on healthy volunteers in Germany under the name VPM1002 in autumn 2008. The safety profile of an active substance is tested in a Phase I trial. The vaccine passed this test with flying colours. No side effects arose in the course of this study. The next thing the researchers must ensure is that VPM1002 is also safe and works as planned in individuals who live in regions with a high incidence of tuberculosis. “The Phase Ib study shows that VPM1002 also fulfils this requirement,” says Bernd Eisele from Vakzine Projekt Management, which is responsible for the implementation of the vaccine trials.

Before VPM1002 can be introduced to the market as a vaccine, its effectiveness and safety must be confirmed in further studies on volunteers in areas with a high risk of tuberculosis. “If everything goes well and VPM1002 also proves effective and safe in large-scale international studies, the new vaccine could be ready for use in around four year’s time,” hopes Stefan Kaufmann.

In addition to VPM1002, eleven other tuberculosis vaccine candidates are currently undergoing clinical development. VPM1002 is the only one of three genetically modified variants of the current BCG vaccine that is undergoing further development in clinical trials. Two of the other candidates, which are based on a virus carrier with Mycobacterium tuberculosis antigens, are currently undergoing Phase IIb trials. The first of these vaccines could be available for use in 2016 at the earliest.

Experts estimate that a vaccine which improves on the BCG could prevent almost 8 million deaths from tuberculosis. A new booster vaccine could reduce the number of tuberculosis victims by a further 40 percent.

Provided by Max-Planck-Gesellschaft